Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $60.
August 30, 2023 | 8:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Apellis Pharmaceuticals and maintained a price target of $60.
The reiteration of a 'Buy' rating by a reputable analyst like Joseph Stringer from Needham is a positive signal for Apellis Pharmaceuticals. The maintained price target of $60 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100